Sansure Biotech Inc - Asset Resilience Ratio
Sansure Biotech Inc (688289) has an Asset Resilience Ratio of 1.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sansure Biotech Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Sansure Biotech Inc's Asset Resilience Ratio has changed over time. See net assets of Sansure Biotech Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sansure Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sansure Biotech Inc (688289) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥141.90 Million | 1.5% |
| Total Liquid Assets | CN¥141.90 Million | 1.50% |
Asset Resilience Insights
- Limited Liquidity: Sansure Biotech Inc maintains only 1.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sansure Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Sansure Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122 |
Medical Instruments & Supplies | 23.52% |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
GETS Global Bhd
KLSE:5079 |
Medical Instruments & Supplies | 0.03% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
Sartorius Aktiengesellschaft
XETRA:SRT3 |
Medical Instruments & Supplies | 4.48% |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN |
Medical Instruments & Supplies | 29.19% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
Annual Asset Resilience Ratio for Sansure Biotech Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Sansure Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.62% | CN¥139.67 Million ≈ $20.44 Million |
CN¥8.60 Billion ≈ $1.26 Billion |
-4.86pp |
| 2023-12-31 | 6.49% | CN¥548.28 Million ≈ $80.23 Million |
CN¥8.45 Billion ≈ $1.24 Billion |
-20.23pp |
| 2022-12-31 | 26.72% | CN¥2.45 Billion ≈ $358.69 Million |
CN¥9.17 Billion ≈ $1.34 Billion |
-2.14pp |
| 2021-12-31 | 28.86% | CN¥2.05 Billion ≈ $299.46 Million |
CN¥7.09 Billion ≈ $1.04 Billion |
-0.49pp |
| 2020-12-31 | 29.36% | CN¥1.60 Billion ≈ $234.31 Million |
CN¥5.45 Billion ≈ $798.15 Million |
+19.03pp |
| 2019-12-31 | 10.32% | CN¥66.33 Million ≈ $9.71 Million |
CN¥642.47 Million ≈ $94.01 Million |
-- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more